Synergistic nanotheranostic platform for fluorescence/magnetic resonance bimodal imaging-guided near infrared photoimmuno-chemodynamic thermal targeting therapy.
11 affiliations
- 1Division of Host Defense Sciences, Dept. of Integrated Health Sciences, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
- 2Graduate School of Medicine, Nagoya University, Nagoya, Japan.
- 3Institute for Advanced Research, Advanced Analytical and Diagnostic Imaging Center (AADIC) / Medical Engineering Unit (MEU), Nagoya University, B3 Unit Frontier, Nagoya, Japan.
- 4Institute for Advanced Research, Nagoya University, Nagoya, Japan.
- 5JSR corporation, Tokyo, Japan.
- 6Graduate School of Engineering, Nagoya University, Nagoya, 464-8603, Japan.
- 7Graduate School of Medicine, Nagoya University, Nagoya, Japan. [email protected].
- 8Institute for Advanced Research, Advanced Analytical and Diagnostic Imaging Center (AADIC) / Medical Engineering Unit (MEU), Nagoya University, B3 Unit Frontier, Nagoya, Japan. [email protected].
- 9Institute for Advanced Research, Nagoya University, Nagoya, Japan. [email protected].
- 10FOREST-Souhatsu, JST, Tokyo, Japan. [email protected].
- 11Institute for Advanced Research, Graduate School of Medicine, Nagoya University, Nagoya, 466-8550, Aichi, Japan. [email protected].
Abstract
Near-infrared (NIR) photoimmunotherapy (PIT) is a promising cancer treatment strategy involving antibody-photoabsorber conjugates. However, the imaging depth and photobleaching susceptibility of the IR700 fluorescence used for treatment monitoring are limited, and antigen heterogeneity within tumors compromises the efficacy of strictly antigen-restricted therapies. We developed a synergistic nanotheranostic platform that integrates NIR-PIT, photothermal therapy, and chemodynamic therapy (CDT) into a single MRI-visible agent (NIR-PICT³). To achieve NIR-PICT³, conjugation of mAb-IRDye700DX (mAb-IR700) to dextran-coated superparamagnetic iron oxide nanoparticles (nanomag-D-spio) yielded nanomag-D-spio-mAb-IR700, enabling dual imaging (IR700 fluorescence/MRI) and targeted cytotoxicity upon 690-nm irradiation. The conjugate retained antigen selectivity, exhibited activatable NIR fluorescence after cellular uptake, generated negative T1- and T2-weighted MRI contrast, and demonstrated robust, cycle-enhanced photothermal performance. Iron-mediated redox catalysis promoted ·OH generation, supporting CDT. In vivo, systemic administration led to marked tumor accumulation, as confirmed by multimodal analyses. Repeated light dosing exploited the NIR-PIT-induced super-enhanced permeability and retention (SUPR) effect, enhancing nanoparticle retention, tumor heating, and therapeutic efficacy. In EGFR+ xenografts, NIR-PICT³ achieved superior tumor regression and survival while inducing photothermal bystander effects in antigen-heterogeneous models. These results establish a modular, image-guided strategy for platform therapy to overcome monitoring depth limitations and antigen heterogeneity in solid tumor NIR-PIT.
Related
- A self-sufficient nanoreactor orchestrating calcium overload and sonodynamic/chemodynamic-amplified ferroptosis for oral squamous cell carcinoma therapy.
- Supervised 3D Virtual Fluorescence and Pseudo-H&E Staining of Fresh Bulk Tissues via Multimodal qOBM and Fluorescence Microscopy
- Fluorescence microscopic evidence for intracellular silicon storage pools in diatoms and their partial separation
- Application of Fluorescence in situ Hybridization in Malignant Hemopathies: First Experience from Albania
- Single-cell DNA cytometry with magnetic- and fluorescence-activated bead sorting
BibTeX
@article{matsuoka2026synergistic,
title = {{Synergistic nanotheranostic platform for fluorescence/magnetic resonance bimodal imaging-guided near infrared photoimmuno-chemodynamic thermal targeting therapy.}},
author = {Kohei Matsuoka and Mizuki Yamada and Ryu Okada and Mibuko Shimada and Mikina Yoshida and Rika Fukushima and Kanna Umeda and Ayano Ohashi and Chiemi Oka and Ayako Kato and Misae Shimizu and Chiaki Koike and Akira Ito and Mitsuo Sato and Kazuhide Sato},
journal = {Journal of nanobiotechnology},
year = {2026},
month = oct,
doi = {10.1186/s12951-026-05148-w},
url = {https://europepmc.org/article/MED/42907901},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Synergistic nanotheranostic platform for fluorescence/magnetic resonance bimodal imaging-guided near infrared photoimmuno-chemodynamic thermal targeting therapy.
AU - Kohei Matsuoka
AU - Mizuki Yamada
AU - Ryu Okada
AU - Mibuko Shimada
AU - Mikina Yoshida
AU - Rika Fukushima
AU - Kanna Umeda
AU - Ayano Ohashi
AU - Chiemi Oka
AU - Ayako Kato
AU - Misae Shimizu
AU - Chiaki Koike
AU - Akira Ito
AU - Mitsuo Sato
AU - Kazuhide Sato
PY - 2026
DA - 2026/10/14
JO - Journal of nanobiotechnology
DO - 10.1186/s12951-026-05148-w
UR - https://europepmc.org/article/MED/42907901
AB - Near-infrared (NIR) photoimmunotherapy (PIT) is a promising cancer treatment strategy involving antibody-photoabsorber conjugates. However, the imaging depth and photobleaching susceptibility of the IR700 fluorescence used for treatment monitoring are limited, and antigen heterogeneity within tumors compromises the efficacy of strictly antigen-restricted therapies. We developed a synergistic nanotheranostic platform that integrates NIR-PIT, photothermal therapy, and chemodynamic therapy (CDT) into a single MRI-visible agent (NIR-PICT³). To achieve NIR-PICT³, conjugation of mAb-IRDye700DX (mAb-IR700) to dextran-coated superparamagnetic iron oxide nanoparticles (nanomag-D-spio) yielded nanomag-D-spio-mAb-IR700, enabling dual imaging (IR700 fluorescence/MRI) and targeted cytotoxicity upon 690-nm irradiation. The conjugate retained antigen selectivity, exhibited activatable NIR fluorescence after cellular uptake, generated negative T1- and T2-weighted MRI contrast, and demonstrated robust, cycle-enhanced photothermal performance. Iron-mediated redox catalysis promoted ·OH generation, supporting CDT. In vivo, systemic administration led to marked tumor accumulation, as confirmed by multimodal analyses. Repeated light dosing exploited the NIR-PIT-induced super-enhanced permeability and retention (SUPR) effect, enhancing nanoparticle retention, tumor heating, and therapeutic efficacy. In EGFR+ xenografts, NIR-PICT³ achieved superior tumor regression and survival while inducing photothermal bystander effects in antigen-heterogeneous models. These results establish a modular, image-guided strategy for platform therapy to overcome monitoring depth limitations and antigen heterogeneity in solid tumor NIR-PIT.
SN - 1477-3155
ER -